These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
348 related items for PubMed ID: 18854723
1. Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies. Emsley R, Berwaerts J, Eerdekens M, Kramer M, Lane R, Lim P, Hough D, Palumbo J. Int Clin Psychopharmacol; 2008 Nov; 23(6):343-56. PubMed ID: 18854723 [Abstract] [Full Text] [Related]
4. Paliperidone extended-release tablets in patients with recently diagnosed schizophrenia. Canuso CM, Bossie CA, Amatniek J, Turkoz I, Pandina G, Cornblatt B. Early Interv Psychiatry; 2010 Feb; 4(1):64-78. PubMed ID: 20199482 [Abstract] [Full Text] [Related]
5. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Marder SR, Kramer M, Ford L, Eerdekens E, Lim P, Eerdekens M, Lowy A. Biol Psychiatry; 2007 Dec 15; 62(12):1363-70. PubMed ID: 17601495 [Abstract] [Full Text] [Related]
12. A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia. Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M, Hough D. J Psychopharmacol; 2011 May 15; 25(5):685-97. PubMed ID: 20615933 [Abstract] [Full Text] [Related]
15. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia. Kane JM, Lauriello J, Laska E, Di Marino M, Wolfgang CD. J Clin Psychopharmacol; 2008 Apr 15; 28(2 Suppl 1):S29-35. PubMed ID: 18334910 [Abstract] [Full Text] [Related]
16. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia. Li H, Rui Q, Ning X, Xu H, Gu N. Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun 01; 35(4):1002-8. PubMed ID: 21315787 [Abstract] [Full Text] [Related]
17. Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials. Weiden PJ, Cutler AJ, Polymeropoulos MH, Wolfgang CD. J Clin Psychopharmacol; 2008 Apr 01; 28(2 Suppl 1):S12-9. PubMed ID: 18334908 [Abstract] [Full Text] [Related]
18. Medication satisfaction in schizophrenia: a blinded-initiation study of paliperidone extended release in patients suboptimally responsive to risperidone. Canuso CM, Grinspan A, Kalali A, Damaraju CV, Merriman U, Alphs L, Awad AG. Int Clin Psychopharmacol; 2010 May 01; 25(3):155-64. PubMed ID: 20216424 [Abstract] [Full Text] [Related]
19. A randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescents. Singh J, Robb A, Vijapurkar U, Nuamah I, Hough D. Biol Psychiatry; 2011 Dec 15; 70(12):1179-87. PubMed ID: 21831359 [Abstract] [Full Text] [Related]
20. Flexible dosing with paliperidone ER in the treatment of patients with acutely exacerbated schizophrenia: results from a single-arm, open-label study. Schmauss M, Jukić V, Siracusano A, Bidzan L, Badescu GM, Maciulis V, Lahaye M, Hoeben D, Tessier C, Schreiner A. Curr Med Res Opin; 2012 Aug 15; 28(8):1395-404. PubMed ID: 22746355 [Abstract] [Full Text] [Related] Page: [Next] [New Search]